Project

Back to overview

Advanced quantitative MRI biomarkers of Parkinson's Disease - towards in-vivo histology

English title Advanced quantitative MRI biomarkers of Parkinson's Disease - towards in-vivo histology
Applicant Lutti Antoine
Number 184784
Funding scheme Project funding
Research institution Laboratoire de Recherche en Neuroimagerie Departement de Neuroscience Cliniques CHUV
Institution of higher education University of Lausanne - LA
Main discipline Neurophysiology and Brain Research
Start/End 01.10.2019 - 30.09.2023
Approved amount 480'480.00
Show all

All Disciplines (3)

Discipline
Neurophysiology and Brain Research
Technical Physics
Other disciplines of Physics

Keywords (7)

Quantitative MRI; Physiological noise; Magnetic Resonance Imaging; In-vivo histology; Parkinson's Disease; Brain iron accumulation; Neuroscience

Lay Summary (French)

Lead
L’IRM quantitative permet de caractériser des propriétés microscopiques du tissu cérébral, in-vivo et de manière non invasive. Toutefois, le manque de spécificité des marqueurs IRM actuels ne permet pas une description précise de l’évolution de la maladie. Ce projet vise à la validation de nouveaux marqueurs IRM et à leur application à l’étude de la maladie de Parkinson.
Lay summary

Contenu et objectifs du travail de recherche

Le paramètre IRM R2* augmente avec la concentration en fer dans les régions sous-corticales. Toutefois, cette augmentation a lieu dans de multiples maladies ainsi que lors du vieillissement sain, et R2* ne constitue donc pas un marqueur spécifique de la maladie de Parkinson. Ce projet propose le développement de marqueurs IRM sensibles à la distribution du fer dans les tissus, spécifique dans la maladie de Parkinson. Des stratégies de mitigations des effets physiologiques sur les données sont proposées afin d’obtenir un haut niveau de précision chez les patients.  

Contexte scientifique et social du projet de recherche

Ce projet vise à fournir de nouveaux biomarqueurs de la maladie de Parkinson. L’objectif est d’améliorer la précision des diagnostiques et de permettre un meilleur suivi de la maladie chez les patients.

 

Direct link to Lay Summary Last update: 03.09.2019

Responsible applicant and co-applicants

Employees

Name Institute

Project partner

Associated projects

Number Title Start Funding scheme
202276 Characterizing heart failure with preserved ejection fraction - an integrative approach that combines quantitative MRI, metabolomics, and genomics with machine learning 01.09.2021 Sinergia

Abstract

Iron concentration in the brain is commonly measured in-vivo with the MRI parameter R2*. However, iron accumulation takes place in numerous neurodegenerative diseases and in healthy ageing, making R2* an unspecific biomarker of neurodegeneration. In this proposal, we offer to develop new MRI biomarkers of brain tissue, specifically sensitive to the distribution of iron stores in Parkinson’s Disease. These biomarkers are the parameters of the Andersson-Weiss (AW) theory. The extraction of AW parameter values in-vivo present methodological challenges that we address in this application. The aims of the proposal are:-To develop MRI acquisition techniques that enable the extraction of accurate AW parameter values from in-vivo data.-To identify the features of the microscopic distribution of iron stores that drive the value of these parameters.-To establish the signature of healthy ageing and Parkinson’s Disease provided by these parameters.This project is expected to produce:-Novel MRI acquisition schemes that mitigate the effects of patients’ physiology on brain quantitative MRI data-If successful, a specific signature of Parkinson’s Disease will be achieved, validating these parameters as biomarkers of the disease, with potential for enhanced diagnostic accuracy and improved monitoring of disease evolution.The project will have an impact in the following fields: -The proposed work is primarily expected to impact clinical and fundamental neuroscience research on Parkinson’s Disease. However, we expect that the scope of the proposed biomarkers will be extended towards the characterization of other neurodegenerative diseases (e.g. Alzheimer’s Disease).-In general terms, this work is a step towards the parallel study of changes in the microscopic properties of the brain and clinical phenotype. We therefore expect a strong interest for these biomarkers from biologists and clinicians alike.-From the methodological perspective, we expect that the proposed mitigation schemes will be extended to other types of MRI acquisition. Also, this work can be paralleled with recent developments in diffusion MRI, where traditional markers are being replaced by others with higher specificity, with a strong impact on the MRI community. The proposed work is the equivalent for relaxometry, the estimation of the relaxation times of the MRI signal.
-